Form 4: Astria Therapeutics Director Hugh Cole Reports Stock Option Grant
SEC Form 4 Filing
Director Hugh Cole reports the acquisition of stock options in Astria Therapeutics, Inc.
Summary
- Hugh M Cole, a director of Astria Therapeutics, Inc., reported a transaction on June 5, 2024.
- Cole acquired 14,100 stock options with an exercise price of $9.18.
- The options vest on June 4, 2025, one year after the grant date, contingent upon continued service as a director.
- Following the transaction, Cole directly owns 14,100 derivative securities.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing related to stock option grants, with neutral sentiment.
Positives
- The grant of stock options to a director aligns their interests with those of the shareholders.
Future Outlook
The document does not contain any specific forward-looking statements regarding the company's future performance.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.
Stakeholder Impact
- The stock option grant could incentivize the director to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| 06/05/2024 | Date of stock option grant |
| 06/04/2034 | Expiration date of the stock options |
| 06/04/2025 | Vesting date of the stock options |
| 06/06/2024 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.